Appili Therapeutics Inc Ordinary Shares APLI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APLI is a good fit for your portfolio.
News
-
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
-
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
-
Appili Therapeutics' Licensing Partner Gets FDA Approval for Metronidazole Oral Suspension
Trading Information
- Previous Close Price
- CAD 0.04
- Day Range
- CAD 0.04–0.04
- 52-Week Range
- CAD 0.03–0.08
- Bid/Ask
- CAD 0.03 / CAD 0.04
- Market Cap
- CAD 4.85 Mil
- Volume/Avg
- 1,000 / 227,671
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
Valuation
|
Metric
|
APLI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 4.22 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
APLI
|
|---|---|
Quick Ratio | 0.41 |
Current Ratio | 0.46 |
Interest Coverage | −2.12 |
Quick Ratio
APLI
Profitability
|
Metric
|
APLI
|
|---|---|
Return on Assets (Normalized) | −211.80% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
APLI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zskqmljtqh | Qnyml | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hvcmxxjp | Zbrny | $110.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rtknbxgs | Sgbrvrc | $107.6 Bil | |
MRNA
| Moderna Inc | Cvjnwqpf | Lzmgf | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Nftdqgfj | Kshjd | $22.3 Bil | |
ARGX
| argenx SE ADR | Clccdlpgm | Lwjrq | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rmccqrz | Bcnlht | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ydhfpfgs | Tnfmbzr | $15.3 Bil | |
INCY
| Incyte Corp | Xrpjtgxdl | Ztlzwb | $13.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tgvpfcvddc | Lyrptx | $12.8 Bil |